144 related articles for article (PubMed ID: 38357420)
1. Cholangiocarcinoma across England: Temporal changes in incidence, survival and routes to diagnosis by region and level of socioeconomic deprivation.
Tataru D; Khan SA; Hill R; Morement H; Wong K; Paley L; Toledano MB
JHEP Rep; 2024 Mar; 6(3):100983. PubMed ID: 38357420
[TBL] [Abstract][Full Text] [Related]
2. The epidemiological trends of biliary tract cancers in the United States of America.
Jiang Y; Jiang L; Li F; Li Q; Yuan S; Huang S; Fu Y; Yan X; Chen J; Li H; Li S; Liu J
BMC Gastroenterol; 2022 Dec; 22(1):546. PubMed ID: 36581813
[TBL] [Abstract][Full Text] [Related]
3. Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013.
Van Dyke AL; Shiels MS; Jones GS; Pfeiffer RM; Petrick JL; Beebe-Dimmer JL; Koshiol J
Cancer; 2019 May; 125(9):1489-1498. PubMed ID: 30645774
[TBL] [Abstract][Full Text] [Related]
4. Epidemiologic patterns of biliary tract cancer in the United States: 2001-2015.
Koshiol J; Yu B; Kabadi SM; Baria K; Shroff RT
BMC Cancer; 2022 Nov; 22(1):1178. PubMed ID: 36384474
[TBL] [Abstract][Full Text] [Related]
5. Disparities in care and outcomes for primary liver cancer in England during 2008-2018: a cohort study of 8.52 million primary care population using the QResearch database.
Liao W; Coupland CAC; Innes H; Jepsen P; Matthews PC; Campbell C; ; Barnes E; Hippisley-Cox J
EClinicalMedicine; 2023 May; 59():101969. PubMed ID: 37200996
[TBL] [Abstract][Full Text] [Related]
6. Regional variation in routes to diagnosis of cholangiocarcinoma in England from 2006 to 2017.
Zalin-Miller A; Jose S; Knott C; Paley L; Tataru D; Morement H; Toledano MB; Khan SA
World J Gastroenterol; 2023 Jun; 29(24):3825-3842. PubMed ID: 37426314
[TBL] [Abstract][Full Text] [Related]
7. Menopausal hormone therapy and risk of biliary tract cancers.
Jackson SS; Pfeiffer RM; Gabbi C; Anderson L; Gadalla SM; Koshiol J
Hepatology; 2022 Feb; 75(2):309-321. PubMed ID: 34766362
[TBL] [Abstract][Full Text] [Related]
8. Incidence and mortality trends for biliary tract cancers in Austria.
Pinter M; Hucke F; Zielonke N; Waldhör T; Trauner M; Peck-Radosavljevic M; Sieghart W
Liver Int; 2014 Aug; 34(7):1102-8. PubMed ID: 24119058
[TBL] [Abstract][Full Text] [Related]
9. Incidence and survival for hepatic, pancreatic and biliary cancers in England between 1998 and 2007.
Coupland VH; Kocher HM; Berry DP; Allum W; Linklater KM; Konfortion J; Møller H; Davies EA
Cancer Epidemiol; 2012 Aug; 36(4):e207-14. PubMed ID: 22534487
[TBL] [Abstract][Full Text] [Related]
10. Age specific trends in mortality disparities by socio-economic deprivation in small geographical areas of England, 2002-2018: A retrospective registry study.
Kraftman L; Hardelid P; Banks J
Lancet Reg Health Eur; 2021 Aug; 7():100136. PubMed ID: 34557841
[TBL] [Abstract][Full Text] [Related]
11. Statins associate with lower risk of biliary tract cancers: A systematic review and meta-analysis.
Cheung KS; Yeung YWM; Wong WS; Li B; Seto WK; Leung WK
Cancer Med; 2023 Jan; 12(1):557-568. PubMed ID: 35698295
[TBL] [Abstract][Full Text] [Related]
12. Trends in Receipt of Adjuvant Chemotherapy and its Impact on Survival in Resected Biliary Tract Cancers.
Rhodin KE; Liu A; Bartholomew A; Kramer R; Parameswaran A; Uronis H; Strickler J; Hsu D; Morse MA; Shah KN; Herbert G; Zani S; Nussbaum DP; Allen PJ; Lidsky ME
Ann Surg Oncol; 2023 Aug; 30(8):4813-4821. PubMed ID: 37188803
[TBL] [Abstract][Full Text] [Related]
13. Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation.
Burton A; Tataru D; Driver RJ; Bird TG; Huws D; Wallace D; Cross TJS; Rowe IA; Alexander G; Marshall A;
JHEP Rep; 2021 Apr; 3(2):100232. PubMed ID: 33748727
[TBL] [Abstract][Full Text] [Related]
14. Tumour stage and overall survival in patients with intrahepatic cholangiocarcinoma and primary sclerosing cholangitis - a retrospective cohort study.
Schramm C; Sapuk A; Hoyer D; Radünz S; Schmidt H
Z Gastroenterol; 2024 Jan; 62(1):37-42. PubMed ID: 38195106
[TBL] [Abstract][Full Text] [Related]
15. Cell of origin in biliary tract cancers and clinical implications.
Moeini A; Haber PK; Sia D
JHEP Rep; 2021 Apr; 3(2):100226. PubMed ID: 33665585
[TBL] [Abstract][Full Text] [Related]
16. Current options and future directions of systemic therapy for advanced biliary tract cancer.
Prete MG; Cammarota A; D'Alessio A; Zanuso V; Rimassa L
Explor Target Antitumor Ther; 2021; 2(5):416-433. PubMed ID: 36045701
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.
Clements O; Eliahoo J; Kim JU; Taylor-Robinson SD; Khan SA
J Hepatol; 2020 Jan; 72(1):95-103. PubMed ID: 31536748
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology of cholangiocarcinoma.
Qurashi M; Vithayathil M; Khan SA
Eur J Surg Oncol; 2023 Sep; ():107064. PubMed ID: 37709624
[TBL] [Abstract][Full Text] [Related]
19. Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017.
Javle M; Lee S; Azad NS; Borad MJ; Kate Kelley R; Sivaraman S; Teschemaker A; Chopra I; Janjan N; Parasuraman S; Bekaii-Saab TS
Oncologist; 2022 Oct; 27(10):874-883. PubMed ID: 35972334
[TBL] [Abstract][Full Text] [Related]
20. Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer.
McNamara MG; Lopes A; Wasan H; Malka D; Goldstein D; Shannon J; Okusaka T; Knox JJ; Wagner AD; André T; Cunningham D; Moehler M; Jensen LH; Koeberle D; Bekaii-Saab T; Bridgewater J; Valle JW
J Hepatol; 2020 Nov; 73(5):1109-1117. PubMed ID: 32446715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
